Biotech Values

[DewDiligence]

(GILD—as previously posted): A P/E ratio of 20—which equates to an “earnings yield” of only 5%—is much too high, given the possible loss of exclusivity in a few years for a significant portion of GILD’s HIV franchise. A P/E of 10 is more reasonable for GILD, IMHO.